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Background-—Loop diuretics are highly natriuretic but their short duration of action permits postdiuretic sodium retention, which
limits salt loss unless dietary salt is severely restricted. We tested the hypothesis that a more prolonged duration of action would
enhance salt loss.
Methods and Results-—Ten healthy participants were crossed over between 20 mg of oral immediate-release or extended-release
(ER) torsemide while consuming a fixed diet with 300 mmold1 of Na+. Compared with immediate-release, plasma torsemide after
ER was 59% lower at 1 to 3 hours but 97% higher at 8 to 10 hours as a result of a >3-fold prolongation of time to maximal plasma
concentrations. The relationship of natriuresis to log torsemide excretion showed marked hysteresis, but participants spent twice
as long with effective concentrations of torsemide after ER, thereby enhancing diuretic efficiency. Compared with immediate-
release, ER torsemide did not reduce creatinine clearance and increased fluid (1634385 versus 728445 mL, P<0.02) and Na+
output (9815 versus 4217 mmol, P<0.05) despite an 18% reduction in exposure. Neither formulation increased K+ excretion.
Conclusions-—Torsemide ER prolongs urine drug levels, thereby increasing the time spent with effective drug concentrations,
reduces postdiuretic Na+ retention, and moderates a fall in glomerular filtration rate. It caused significant Na+ loss even during very
high salt intake. Thus, a short duration of action limits salt loss with loop diuretics. These conclusions warrant testing in subjects
with edema and heart failure. ( J Am Heart Assoc. 2017;6:e006135. DOI: 10.1161/JAHA.117.006135.)
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T he prevalence of hypertension, congestive heart failure(CHF), and chronic kidney disease is increasing.1
Cardiovascular disease is the most common cause of death
and disability worldwide,2 thereby encumbering a huge
economic burden.3 Diuretics are the first line of treatment
for these common conditions. The therapeutic effect of
diuretics is dependent on a loss of body Na+ and fluid.4 Thus,
their effects must be predictable if the burden of cardiovas-
cular disease is to be reduced.
Glomerular filtration rate (GFR) is reduced in most subjects
with edematous conditions, mandating the use of loop
diuretics since these agents have the most potent acute
pharmacological action of natriuresis and diuresis.
Despite their unrivaled acute natriuretic effectiveness, loop
diuretics have been inadequate therapeutic agents. They are
associated with several adverse effects including electrolyte
and metabolic disturbances and reduction in GFR.5–10
Furosemide causes little reduction in blood pressure (BP) in
subjects with hypertension with preserved renal function.11,12
Loop diuretics are usually preferred for subjects with chronic
kidney disease. However, thiazides are usually preferred to
treat subjects with hypertension if the GFR is not reduced.
Furosemide has been shown to have poor and highly variable
bioavailability that is worsened in decompensated CHF,13,14
and this may account, at least in part, for the unpredictable
effects of furosemide in treating subjects with CHF.14
Bumetanide is even more short acting. This has prompted
suggestions that furosemide be replaced as the loop diuretic
of choice by the more predictable torsemide, which is largely
eliminated by the metabolism, has a high bioavailability even
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in subjects with CHF and chronic kidney disease, and causes
little or no hypokalemia.7,9
The short duration of action of 2 to 4 hours of all loop
diuretics after oral dosing is a class defect that can lead to 3
problems. First, the urinary concentration of the loop diuretic
resides within the therapeutic range for only a short
period.10,15 Second, the abrupt but short-lived natriuresis
leaves 20 hours for the kidney to regain the salt and water
lost before the next daily dose.8,12,16–19 These attributes
account for the failure of furosemide and bumetanide to cause
net Na+ loss over 1 to 3 days of once-daily administration to
normal subjects unless dietary salt is restricted to below
120 mmold1.8,16,18 Third, the torrential acute diuresis
(“Niagara effect”) can cause incontinence in subjects with
impaired bladder control.20
We studied a novel extended-release (ER) formulation of
torsemide that delivers the drug into solution over 8 to
10 hours (Figure 1) to test the hypothesis that the inability
of a single dose of a loop diuretic to deplete the body of
salt and water during high salt intake is caused by a limited
duration of action on the kidney. We compared the effects
of 20 mg of oral torsemide as an immediate-release (IR) or
ER formulation given to 10 healthy volunteers consuming a
fixed high-salt diet containing 300 mmol Na+ daily. We
measured pharmacokinetics, creatinine clearance (CCR), and
patterns of electrolyte and water excretion after drug
administration to assess the mechanisms of any differ-
ences.
Methods
Drug Formulation
This study compared torsemide IR (Demadex Rx) with a novel
release (ER) formulation prepared by Sarfez, Inc as a matrix-
based ER formulation with specific ratios of hydroxypropyl
methylcellulose to microcrystalline cellulose. The IR
preparation delivered >80% of the drug into solution within
1 to 2 hours, whereas the ER formulation released this
fraction over 10 to 12 hours (Figure 1).
Study Participants
Ten healthy volunteers, aged 21 to 45 years, were recruited.
Each gave informed consent to participate. The study was
passed by the LiLine Hospital ethics committee, Basavesh-
wara Nagar, Bangalore-560079. It was assigned the Drug
Controller General of India (equivalent of the US Foods
Holding Corp) No. T-BE-296/13. Participants were not
selected on the basis of sex or race/ethnic background.
They had no significant medical history, were not taking
medications, and had normal values for serum urea nitrogen,
serum creatinine, plasma electrolytes, liver function tests,
hemogram, and urinalysis. All participants had a BP <140/
90 mm Hg. Their body weight ranged from 61.2 to 73.0 kg.
Trial Design
Each participant received both of the torsemide formulations
in a randomized crossover design separated by a 3-week
washout period. The participants, the investigators, and those
analyzing the results were unaware of the allocation to IR or
ER formulation.
Subjects were preconsented, admitted to the study unit,
and received fixed constant daily meals for 3 days containing
300 mmol of Na+ and 45 mmol of K+. Subjects remained in
the metabolic department throughout the study period
without visitors. Each meal was observed to ensure that all
Figure 1. Torsemide dissolution in vitro. Mean values (n=2) for
delivery of torsemide from 20 mg tablets into a stirred solution of
0.154 molL1 NaCl at 37°C. Solid circles and continuous lines
indicate immediate-release torsemide; open circles and dashed
lines, extended-release torsemide.
Clinical Perspective
What Is New?
• This crossover study in 10 normal volunteers consuming a
high salt intake revealed that an extended-release formu-
lation of torsemide doubled the daily loss of sodium and
fluid compared with the standard immediate-release prepa-
ration.
What Are the Clinical Implications?
• This is the first demonstration that a single dose of a loop
diuretic can cause negative salt balance in persons with a
very high salt intake.
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of the food was consumed. This provided strict control of Na+
and K+ intakes. Fluid was allowed ad libitum. BP and heart
rate were measured using an automated device after 2 min-
utes of sitting. Subjects fasted for 12 hours prior to receiving
the diuretic on day 3, and for 4 hours thereafter to allow for
pharmacokinetic studies in the fasting state. To compensate
for reduced salt intake (50 mmol of Na+) during the breakfast
period, they received 233 mL of 0.154 molL1 saline
solution immediately before drug administration. During day
2 and 3 (the day before and the day of the diuretic), subjects
collected a 24-hour urine sample with additional recordings of
timed excretion after the diuretic. Immediately before inges-
tion, and for 24 hours thereafter, blood and urine samples
were taken at designated times. Aliquots of 2 mL of the urine
were taken for analysis and the remainder added to a 24-hour
collection. Blood and urine were sampled at 30-minute
intervals for 3 hours after diuretic administration (0–3 hours),
then hourly (3–4 hours), then 2 hourly (4–14 hours), and
finally at 14 and 23 hours. At zero time, they received 20 mg
of torsemide (IR or ER) with 330 mL of water. After
completion of the study, subjects’ BP and heart rate were
recorded in the sitting position, and the subjects were then
discharged.
Analyses
Urine samples were measured for volume and 1 mL aliquots
taken for measurement of Na+, K+, and creatinine concentra-
tions in an automated apparatus and 1 mL for torsemide
concentration. Plasma and urine samples were extracted and
analyzed for torsemide by a validated capillary zone elec-
trophoresis method that recorded no signal in predrug
samples of urine and plasma.21
Statistical Analysis
MeanSEM data were calculated for each drug period in each
individual. To test the hypothesis, within-subject paired t tests
were used to assess differences in 24-hour excretion of Na+
and fluid after the IR versus ER preparations. The multiple P
values reported for differences in parameters at different
times after torsemide ER and IR were considered descriptive
of the patterns of change observed after the 2 formulations. A
P<0.05 was considered statistically significant.
Results
All 10 subjects completed both arms of the trial without any
adverse effects.
The patterns of fluid, CCr, and Na
+ and K+ excretion
following diuretic administration are shown in Figure 2. The
rate of fluid excretion and urinary excretion of sodium (UNaV)
increased rapidly with the IR and ER preparations to a
maximum at 1.0 to 1.5 hours, respectively (Figure 2A and
2C), and remained similar until 2.5 hours, after which the
excretions were higher with the ER than IR formulations, until
12 hours when excretion was low with both formulations.
The rate of fluid excretion and UNaV fell below prior levels by
4 hours after the IR but not until 12 hours after the ER
administration. Potassium excretion increased sharply with
both preparations and remained elevated for 4 hours
(Figure 2D) but, after 12 hours, fell to levels mostly below
the prior day in both groups. There was an initial sharp
increase in CCr during the first 0.5 to 1 hour after adminis-
tration of both IR and ER torsemide (Figure 2B), but this
returned promptly to baseline and was reduced below
baseline at 2 hours, where it largely remained thereafter.
The pharmacokinetic data are shown in the Table. Com-
pared with IR, the peak serum concentration with ER was
reduced by 69% and the overall area under the curve (AUC)
was reduced by 18% to 21%. The time to reach peak serum
concentration of ER was prolonged >3-fold. There was a 59%
reduction in AUC from 1 to 3 hours but a 97% increase in AUC
from 8 to 10 hours.
The plasma torsemide concentrations rose rapidly after IR
to peak within 1 hour, but the peak was delayed to3.5 hours
after ER (Figure 3A). Thereafter, the concentrations declined
log-linearly but were several-fold higher after ER throughout the
remainder of the day. Renal torsemide excretion followed a
similar time course (Figure 3B). The relationship of increases in
UNaV above basal values to the log of renal torsemide excretion
(an index of natriuretic effect related to the delivery of drug to
its active site) showed marked hysteresis (Figure 3C). There
was a sharp rise in UNaV with log torsemide excretion during
the initial ascending phase followed by an inflection and a
much reduced natriuresis relative to torsemide excretion
during the declining phase. Subjects spent twice as long in the
early ascending phase after torsemide ER than IR. This resulted
in a greater natriuretic efficiency as indexed by change in Na+
excreted per log torsemide excreted (Figure 3D).
The mean changes for 24 hours after torsemide IR or ER,
compared with the prior 24 hours, and the mean differences
between the changes produced by the two formulations are
shown in Figure 4. Fluid excretion was not significantly
changed after IR but was increased after ER, resulting in a 2.2-
fold greater fluid loss of 906 mL (Figure 4A). The UNaV was
increased after both IR and ER but was 2.2-fold greater after
ER (Figure 4B). The increase in UnaV did not differ whether
torsemide ER or IR were given as first exposure or after the 3-
week washout period. The UnaV with torsemide ER on first and
second exposure was +8916 versus +10618 and with
torsemide IR was +4818 versus +3720 mmold1. Nei-
ther drug changed 24-hour potassium excretion (Figure 4C).
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The CCr was reduced by 25% following IR but was not
significantly changed following ER (Figure 4D). Body weight
was reduced only after the ER (Figure 4E). Neither IR nor ER
changed mean BP, but there was a significant difference
between the two with a small net fall of 4 mm Hg after ER
versus IR (Figure 4F).
Discussion
Themainnewfindings from this studyof healthy subjects are that
a novel ER formulation of torsemide that delivers the drug into
solution over 10 to 12 hours prolonged the natriuresis and
diuresis and doubled the loss of fluid, body weight, and Na+
without a significant fall in GFR. The diuresis was followed by
sustained renal fluid and Na+ retention, but this postdiuretic
period was shortened after torsemide ER from 18 to
12 hours. Neither formulation led to a significant loss of
potassium. The ER formulation prolonged the time to maximal
plasma torsemide concentration by 3.5-fold, with a correspond-
ing reduction in torsemide AUC at 1 to 3 hours of 59%, but a
doubling of AUC at 8 to 10 hours. The overall exposure to
torsemide ERwas reduced by 18%. Themore gradual rise to peak
renal torsemide excretion prolonged the time that the drug
remained in the highly effective ascending phase of the
hysteretic relationship between increase in urinary Na+ excretion
above basal and log renal torsemide excretion, thereby increas-
ing Na+ excreted per unit torsemide excreted (natriuretic
efficiency). Thus, torsemide ER reduced postdiuretic Na+ recla-
mation,maintainedGFR, and enhanced natriuretic efficiency that
Table. Pharmocokinetic Parameters After Administration of
Torsemide
IR or ER Torsemide
Parameter IR ER P Value
CMAX, ngmL1 2962412 90593 <0.001
AUC0-t, h*ngmL1 6493688 5125552 <0.001
AUCo-inf, h*ngmL1 6728704 5543565 <0.001
Tmax, h 1.030.13 3.530.27 <0.001
AUC1–3, h*ngmL1 2966294 1225161 <0.001
AUC8–10, h*ngmL1 20332 40050 <0.001
MeanSEM values (n=10 per group). AUC indicates area under the curve; CMAX, peak
serum concentration; ER, extended-release; IR, immediate-release; Tmax, time to reach
peak serum concentration.
Figure 2. Fluid and electrolyte excretion and creatinine clearance after torsemide. MeanSEM values (n=10 per group) comparing responses
to 20 mg of torsemide immediate-release (continuous lines) or extended-release (dashed lines). A, urine flow; (B) creatinine clearance; (C)
sodium excretion; (D) potassium excretion. The mean values for the previous 24 hours are indicated by the horizontal dotted lines. Comparing
values at the same time points after dosing with immediate-release torsemide or extended-release torsemide: *P<0.05; **P<0.01; ***P<0.005.
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together resulted in greater Na+, fluid, and body weight loss after
a single dose despite a somewhat reduced bioavailability.
The daily Na+ intake of 300 mmol matched prior studies
with furosemide.8,16 The IR formulation of torsemide (20 mg)
did not induce fluid or weight loss and led to a modest net Na+
loss of 42 mmol. Similar studies with furosemide (40 mg) or
bumetanide (1 mg) demonstrated no overall fluid, weight, or
Na+ loss at 24 hours after dosing8,16 despite similar initial
large increases in Na+ excretion. The significant, albeit
modest, Na+ loss with torsemide IR in this study may relate
to the slightly increased duration of natriuresis of 4 hours
compared with 2 to 3 hours after furosemide or bumetanide.
Two factors have been identified to account for the failure of
loop diuretics to induce a consistent loss of Na+ and fluid without
dietary salt restriction. First, Brater and colleagues15 related this
to the limited time during which the urinary diuretic concentra-
tions are within the 25% to 75% of maximal effective concentra-
tion (“most efficient” concentration). This period was increased
from 2 hours after torsemide IR to 4 to 8 hours after
torsemide ER (Figure 2). Second is a prolonged postdiuretic
period of Na+ and fluid retention8,16 that can fully offset even an
intense initial short-lived natriuresis unless dietary salt is
restricted.8,16 While some negative Na+ balance occurs with
moderate (120 mmold1) or severe (20 mmold1) restriction
of dietary Na+,18 this is difficult to achieve in clinical practice. This
may account for the disappointing effects of loop diuretics as
antihypertensive agents11 or as drugs to treat uncompensated
CHF.9 The present findings that an ER formulation of torsemide
inducedfluid, bodyweight, andNa+ loss, despite a 300mmold1
Na+ intake, suggests that this may be the first loop diuretic
formulation that does not require dietary salt restriction and
monitoring of Na+ intake (from Na+ excretion) for efficacy.
Hypokalemia is a prominent adverse effect of furosemide,
bumetanide, and thiazide diuretics. Torsemide does not rou-
tinely reduce serum potassium concentration (SK) and prevents
thiazide-induced K+ loss in rat models.22 Neither formulation of
torsemide increased K+ excretion significantly in this study. The
absence of kaliuresis after torsemide administration may relate
to blockade of the mineralocorticosteroid receptors23 or
reduction of aldosterone secretion.24 The absence of
Figure 3. Torsemide kinetics and relationships to natriuresis. Mean (SEM values) for plasma torsemide concentration (A), renal torsemide
excretion (B), changes in sodium excretion related to renal torsemide excretion (log scale) (C), and torsemide natriuretic efficiency (D) comparing
immediate-release (IR) torsemide (solid circles) with extended-release (ER) torsemide (open circles).
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hypokalemia and the high and predictable bioavailability have
led to the suggestion that torsemide be the preferred loop
diuretic.7,9,13,25 Indeed, subjects randomized to torsemide
compared with furosemide for uncompensated CHF had a
reduced rate of readmission for recurrent CHF, and a more cost-
effective treatment.25
The remarkable and rapid development of within-dose
tolerance may underlie the modest or indeed nonsignificant
increase in Na+ excretion with a continuous intravenous
infusion of a loop diuretic compared with an equivalent
single oral dose.26,27 Thus, intravenous infusion is not a
reliable strategy to enhance natriuresis despite continuous
delivery of the diuretic to its site of action.
Furosemide given to healthy subjects reduces 24-hour
CCr by 23%,8 which is comparable to the pattern observed
after torsemide IR in this study. A fall in GFR compromises
Figure 4. Excretion of fluid (UV; A), sodium (UNaV; B) and potassium (UKV; C); creatinine clearance (CCR; D); body weight (BWt; E); and mean
blood pressure (MBP; F). Individual paired values for the changes in the 24 hours after torsemide from the prior 24 hours, comparing immediate-
release (IM) (open boxes) and extended-release (ER) (crosshatched boxes) torsemide and differences (solid boxes) in the changes produced by
torsemide ER vs IR. Significance of difference from prior, prediuretic day: *P<0.05; ***P<0.005. Significance of difference between changes
with ER vs IR: †P<0.05.
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the fluid and salt-depleting actions of the diuretic.28 The
cause for the fall in GFR is unclear,5,11 but the GFR was
better preserved after ER torsemide in this study. Whether
this will translate into better preservation of renal function
during long-term therapy with torsemide ER requires further
study.
Previous studies have reported that a slow-release formu-
lation of furosemide has a somewhat improved antihyperten-
sive efficacy,29–33 but the low and variable bioavailability is
worsened, which led to its discontinuation. Two ER formula-
tions of torsemide have been developed. One was abandoned
and the other improved antihypertensive efficacy only mod-
estly and failed to improve fluid or electrolyte excretion likely
because it prolonged the time to reach peak serum concen-
tration only slightly.34–36
Study Limitations
We acknowledge some limitations of this study. First,
participants were equilibrated to Na+ intake over 2 days,
whereas we had previously used 3 days.8,16,17 However,
during prolonged fixed levels of Na+, the individual 24-hour
Na+ excretion varies considerably.37–39 Importantly, the daily
meals were identical during the two phases of the protocol.
Therefore, differences in Na+ excretion with torsemide ER
versus IR cannot be ascribed to differences in Na+ intake.
Second, this study has a limited sample size of 10 partici-
pants. It should be followed up in a larger study of a group of
subjects with edema.
Conclusions
An ER formulation of torsemide that increases drug delivery
into solution from 2 to 12 hours doubled daily fluid and Na+
loss and mitigated significant reductions in GFR. Further
studies over a more prolonged period in target patient
populations will be required to test whether these short-term
beneficial effects in healthy subjects translate into enhanced
therapeutic efficacy.
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